Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “neutral” rating reissued by research analysts at Cantor Fitzgerald in a report issued on Tuesday. They currently have a $27.00 target price on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 73.97% from the stock’s previous close.

Other research analysts also recently issued research reports about the company. Vetr downgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 target price for the company. in a research note on Thursday, June 22nd. BidaskClub downgraded Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 16th. Citigroup Inc. downgraded Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $32.00 to $19.00 in a research note on Wednesday, August 16th. Maxim Group reissued a “hold” rating and set a $35.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, July 13th. Finally, Credit Suisse Group reissued an “outperform” rating and set a $39.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Five analysts have rated the stock with a sell rating, twenty have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries Limited presently has a consensus rating of “Hold” and an average price target of $33.71.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 15.52 on Tuesday. Teva Pharmaceutical Industries Limited has a 12-month low of $15.22 and a 12-month high of $52.66. The company’s market cap is $15.77 billion. The stock has a 50 day moving average of $21.96 and a 200 day moving average of $29.37.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The firm’s revenue was up 12.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.25 EPS. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Stock Rating Reaffirmed by Cantor Fitzgerald” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/07/teva-pharmaceutical-industries-limited-teva-stock-rating-reaffirmed-by-cantor-fitzgerald.html.

Large investors have recently modified their holdings of the company. San Francisco Sentry Investment Group CA acquired a new position in shares of Teva Pharmaceutical Industries Limited during the second quarter worth approximately $106,000. Bronfman E.L. Rothschild L.P. raised its position in shares of Teva Pharmaceutical Industries Limited by 7.8% during the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after purchasing an additional 261 shares during the period. Kistler Tiffany Companies LLC raised its position in shares of Teva Pharmaceutical Industries Limited by 74.7% during the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after purchasing an additional 1,571 shares during the period. FNY Managed Accounts LLC acquired a new position in shares of Teva Pharmaceutical Industries Limited during the first quarter worth approximately $123,000. Finally, Sterling Investment Advisors Ltd. raised its position in shares of Teva Pharmaceutical Industries Limited by 2.6% during the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after purchasing an additional 100 shares during the period. 56.87% of the stock is currently owned by institutional investors.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.